Back to School: How biopharma can reboot drug development. Access exclusive analysis here

ARYx: The path out of toxicity

Although drug discovery companies take steps to eliminate toxic compounds from their portfolios as early as lead optimization, ARYx Pharmaceuticals Inc. believes a better way to tackle potential toxicities is to pay attention to the area most often responsible for toxicity - the molecule's metabolic/elimination pathway.
ARYx uses retrometabolic design to reduce toxicity of compounds acting on well-validated disease pathways. By starting at the end of the drug cycle - with an inactive metabolite - and defining the compound's

Read the full 796 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers